Lantern Pharma Inc., a pharmaceutical company traded under the ticker symbol LTRN, aims to transform the process of cancer drug development through the application of artificial intelligence (AI), machine learning, and genomics. This clinical-stage biopharmaceutical company is headquartered in Dallas, Texas and houses its AI platform and drug development facilities there.
Lantern Pharma develops its drugs through the company’s proprietary artificial intelligence platform, known as the RADR® platform. A vital part of Lantern's business model, RADR®, uses machine learning algorithms to predict the likelihood of success for certain cancer drugs. This approach allows the company to increase the speed and efficiency of cancer drug development, lowering costs and potentially improving patient outcomes. The RADR® platform currently helps guide and accelerate the development of the company’s drug pipeline, which includes three drugs in different stages of clinical development targeting unique and significant unmet needs in oncology.
One of the most promising drugs in Lantern Pharma's pipeline, LP-100, is an investigational treatment for prostate cancer that has shown potential in early clinical trials. The second drug, LP-300, is a potential treatment for non-small cell lung cancer, currently in Phase 2 development phase. The third one, LP-184, is a potential treatment for solid tumors that are responsive to the drug based on genetic markers, currently in the pre-clinical trial phase.
Since its inception in 2013, Lantern Pharma has been working diligently to revolutionize the traditional approach to cancer drug development. The use of AI to identify potential drug candidates sharply contrasts with the typical trial and error method used in pharmaceuticals. As a result, Lantern Pharma has become a beacon of hope due to its approach to accelerating the development of cancer treatments and the potential to bring these therapies to patients faster.
Although the company remains in the clinical phase for its various candidate compounds, it has gained attention from investors and the medical community for its innovative use of technology. With its pioneering use of AI, and a focus on genomic data, Lantern Pharma represents a cutting-edge trend in pharmaceutical development.
In conclusion, Lantern Pharma Inc. is dedicated to transforming cancer drug development using AI and genomics to rapidly identify and develop targeted therapies for patients suffering from a variety of malignancies. Its RADR® platform could significantly reduce the lead times and costs associated with traditional drug development, potentially leading to faster, more effective treatments for patients worldwide.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Lantern Pharma and its subsidiary Starlight Therapeutics announced the peer-reviewed publication of Phase 1a data for LP-184 in recurrent glioblastoma. The data supports a planned Phase 1b/2a combination trial of LP-184 with spironolactone, which has an FDA-cleared IND and is registered as NCT07431216. The publication establishes the recommended dose for expansion and indicates that spironolactone may significantly enhance LP-184's activity against GBM cells.
Lantern Pharma (NASDAQ:LTRN) is expected to report its Q3 2026 earnings on Wednesday, November 11, 2026, with a conference call scheduled for November 12, 2026, at 9:00 AM ET. Analysts anticipate the company will post earnings of -$0.35 per share for the quarter. Lantern Pharma has a history of beating consensus EPS estimates, having done so in 6 of its last 8 quarters.
Lantern Pharma Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on December 1, 2026, where shareholders will vote on seven key proposals. These proposals include increasing authorized common stock to 50 million shares, approving the issuance of up to 3,669,725 common shares for purchase warrants, and expanding the equity incentive plan by 250,000 shares. Stockholders of record as of October 5, 2026, are eligible to vote on director elections and the ratification of EisnerAmper LLP as the independent registered public accounting firm.
Lantern Pharma Inc. (NASDAQ: LTRN), an AI-driven oncology company, announced it will present at the ThinkEquity Conference in New York City on October 15, 2026, at 3:30 p.m. ET. Management will also be available for one-on-one meetings throughout the conference. The company utilizes its proprietary RADR® AI platform to develop targeted cancer therapies and has multiple clinical-stage drug programs.